Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Atopic Dermatitis
In the pilot efficacy study conducted in Switzerland, 15 atopic dermatitis patients (AD) were recruited, with eight treated topically with 0.1% CT327 [cream] twice daily for 15 days and seven receiving placebo. A clinically significant improvement in symptoms was seen after eight days of treatment with CT327 as measured by change in mEASI (modified eczema area and severity index) score from baseline. Onset of efficacy was seen at three to five days of treatment. The greatest patient-reported benefit was in night time itch, one of the most troublesome symptoms of atopic dermatitis. CT327 was shown to be safe and well tolerated with no serious adverse events and no reported site irritation.
CT327 is also currently in Phase IIa proof-of-concept clinical trials in psoriasis and pain. Further proof-of-concept clinical trials in inflammatory pain are planned.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.